- Home
- PROK vs TARA Comparison
PROK vs TARA Comparison
Compare PROK & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROK
- TARA
- Stock Information
- Founded
- PROK 2015
- TARA N/A
- Country
- PROK United States
- TARA United States
- Employees
- PROK N/A
- TARA N/A
- Industry
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- TARA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PROK Health Care
- TARA Health Care
- Exchange
- PROK Nasdaq
- TARA Nasdaq
- Market Cap
- PROK 126.8M
- TARA 136.3M
- IPO Year
- PROK N/A
- TARA N/A
- Fundamental
- Price
- PROK $0.84
- TARA $4.29
- Analyst Decision
- PROK Buy
- TARA Strong Buy
- Analyst Count
- PROK 4
- TARA 4
- Target Price
- PROK $5.00
- TARA $22.67
- AVG Volume (30 Days)
- PROK 434.6K
- TARA 224.3K
- Earning Date
- PROK 05-09-2025
- TARA 03-05-2025
- Dividend Yield
- PROK N/A
- TARA N/A
- EPS Growth
- PROK N/A
- TARA N/A
- EPS
- PROK N/A
- TARA N/A
- Revenue
- PROK $76,000.00
- TARA N/A
- Revenue This Year
- PROK N/A
- TARA N/A
- Revenue Next Year
- PROK N/A
- TARA N/A
- P/E Ratio
- PROK N/A
- TARA N/A
- Revenue Growth
- PROK N/A
- TARA N/A
- 52 Week Low
- PROK $0.80
- TARA $1.60
- 52 Week High
- PROK $4.44
- TARA $10.48
- Technical
- Relative Strength Index (RSI)
- PROK 29.40
- TARA 49.87
- Support Level
- PROK $0.87
- TARA $4.41
- Resistance Level
- PROK $1.00
- TARA $4.63
- Average True Range (ATR)
- PROK 0.10
- TARA 0.29
- MACD
- PROK 0.01
- TARA -0.02
- Stochastic Oscillator
- PROK 14.70
- TARA 42.05
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).